Bailard, Inc. Castle Biosciences Inc Transaction History
Bailard, Inc.
- $3.84 Billion
- Q4 2024
A detailed history of Bailard, Inc. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Bailard, Inc. holds 9,900 shares of CSTL stock, worth $254,925. This represents 0.01% of its overall portfolio holdings.
Number of Shares
9,900
Previous 8,800
12.5%
Holding current value
$254,925
Previous $250,000
5.2%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding CSTL
# of Institutions
210Shares Held
26.6MCall Options Held
128KPut Options Held
35.4K-
Black Rock Inc. New York, NY3.04MShares$78.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$47.2 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.8MShares$46.2 Million0.24% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.44MShares$37 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX999KShares$25.7 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $677M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...